中国制造出世界第一款3D血管生物打印机 （中英双语）
青岛希尼尔翻译咨询有限公司（www.sinosenior.com）整理发布 2015-10-28
青岛希尼尔翻译公司（www.sinosenior.com）2015年10月28日了解到：本周日，中国的一家生物技术公司宣布，它已经研发出了世界上第一台3D血管生物打印机，这使得制造个体功能器官成为可能。
A Chinese biotechnological company announced on Sunday it has developed
the world’s first 3D blood vessel bio-printer, which makes it possible
to produce personalized functional organs.
Sichuan Revotek Co., Ltd. based in Chengdu, capital of southwest
China’s Sichuan Province, said the significant breakthrough has been
achieved through its self-developed stem cell bio-ink technology, 3D
bio-printer and cloud computing platform.
位于中国西南部四川省省会成都的四川Revotek公司称，通过公司自己研发的干细胞生物连接技术、3D生物打印机和云计算平台，3D血管生物打印机这一具有划时代的意义的技术突破已经完成。
"The creative breakthrough in the 3D blood vessel bio-printing means
we have mastered the stem cell-based 3D bio-printing technology," said
Yang Keng, chairman of Sichuan Languang Development Co., Ltd. Revotek is
a subsidiary of Sichuan Languang.
四川蓝光发展公司主席杨铿说，“这一具有创新性的3D血管印刷机的发明，意味着我们已经掌握了干细胞为基础的3D生物打印技术”。Revotek是四川蓝光集团的子公司。
Blood vessels that transport nutrients to organs are indispensable
elements when creating any organs, according to James Kang, an expert
who led the program.
据领导该项目的专家James Kang说，当创造任何器官的时候，向各器官运送营养物质的血管是必不可少的。
Kang’s team has created a novel type of bio-ink - "Biosynsphere",
whose primary goal is the personalized stem cell bio-printing to pave
the way for organ regeneration.
康的研发团队已经创造了一个新的生物链接模式- Biosynsphere，这一链接模式的首要目标是个体干细胞生物打印，以便器官再生。
"We have successfully realized the blood vessel regeneration by
relying on the 3D bio-printer, the biosynsphere technology and the data
model based on cloud computing," he said.
他说，“我们已经成功地通过依赖3D打印机，biosynsphere技术和云计算基础上的数据模型实现了血管再生。”
The company said it is willing to absorb more talent and seek
international cooperation for the application of the achievements.
公司很愿意吸收更多的人才并且寻求国际公司来应用这一成就。来源:人民网
注：部分新闻来源于网路，如有涉及版权，请及时通知我们，我们将尽快删除。
---------------------------------------------------------------------------------------------------------------------------------------------------------------